2023
Assessment of Treatment-Relevant Immune Biomarkers in Psoriasis and Atopic Dermatitis: Toward Personalized Medicine in Dermatology
Mortlock R, Ma E, Cohen J, Damsky W. Assessment of Treatment-Relevant Immune Biomarkers in Psoriasis and Atopic Dermatitis: Toward Personalized Medicine in Dermatology. Journal Of Investigative Dermatology 2023, 143: 1412-1422. PMID: 37341663, PMCID: PMC10830170, DOI: 10.1016/j.jid.2023.04.005.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAtopic dermatitisSkin diseasesInflammatory skin diseaseInflammatory skin conditionImmunologic biomarkersImmune biomarkersPersonalized medicineInflammatory dermatosesImmunologic approachesTherapy selectionSkin conditionsSingle-cell RNA sequencingMolecular profilingBiomarkersTissue stainingPsoriasisDermatitisDiseaseDermatologyRNA sequencingMedicineCurettageDermatosesTherapyPersonalized classification
2017
JAK inhibitors in dermatology: The promise of a new drug class
Damsky W, King BA. JAK inhibitors in dermatology: The promise of a new drug class. Journal Of The American Academy Of Dermatology 2017, 76: 736-744. PMID: 28139263, PMCID: PMC6035868, DOI: 10.1016/j.jaad.2016.12.005.Peer-Reviewed Original ResearchMeSH KeywordsAlopecia AreataAnti-Inflammatory AgentsAzetidinesClinical Trials as TopicDermatitis, AtopicDermatologic AgentsHumansJanus KinasesMolecular Targeted TherapyNitrilesPiperidinesProtein Kinase InhibitorsPsoriasisPurinesPyrazolesPyrimidinesPyrrolesSignal TransductionSkin DiseasesSulfonamidesVitiligoConceptsJAK inhibitorsSoluble inflammatory mediatorsNew drug classesUseful therapeutic strategyDifferent proinflammatoryAtopic dermatitisInflammatory mediatorsInflammatory dermatosesAlopecia areataDrug classesJanus kinase-signal transducerTherapeutic strategiesJAK inhibitionDermatologic therapyKinase-signal transducerTargeted therapeuticsActivator of transcriptionDermatologyJAK-STATInhibitorsPromising new classEarlier reportsInhibition